Latest news about Ambalal Sarabhai Enterprises
Ambalal Sarabhai Enterprises
34.84
+1.35(+4.03%)
Company Performance:
View Company Insights1D+4.03%
1M+6.38%
6M+7.37%
1Y+7.37%
5Y+7.37%
More news about Ambalal Sarabhai Enterprises
13Nov 25
Ambalal Sarabhai Enterprises Reports Q2 Loss Despite Revenue Stability
Ambalal Sarabhai Enterprises Limited (ASE) reported mixed Q2 results with a 0.57% decrease in revenue to Rs 4,444.92 lakhs and a net loss of Rs 56.03 lakhs, down 121.39% year-over-year. The Electronics segment remained profitable with Rs 213.37 lakhs in segment results, while Pharmaceuticals reported a loss of Rs 121.14 lakhs. Half-year revenue reached Rs 8,478.80 lakhs with a net profit of Rs 766.32 lakhs. Total assets stood at Rs 26,019.34 lakhs with total equity of Rs 13,752.35 lakhs as of September 30.
06Nov 25
Ambalal Sarabhai Enterprises' Joint Venture CoSara Diagnostics Explores SPAC Merger
CoSara Diagnostics, a joint venture of Ambalal Sarabhai Enterprises (ASE), is exploring strategic options. Co-Diagnostics Inc., ASE's partner, has engaged Maxim Group LLC to investigate possibilities such as a SPAC merger or listing on a U.S. national securities exchange. This move aims to unlock value for CoSara and its shareholders. CoSara, established in 2017, is a partnership between Co-Diagnostics Inc. and Synbiotics Ltd., focusing on molecular diagnostics products for international markets, particularly India.
27Oct 25
Ambalal Sarabhai's Telerad Division Clinches Top Broadcast Award at Industry Show
Ambalal Sarabhai Enterprises Limited's Telerad division, operating under Systronics India Limited, has been awarded the 'Best Regional Distributor — Broadcast - West Award' at the Broadcast India Show 2025 in Mumbai. Telerad, a leading system integrator in the broadcast industry, is recognized for providing comprehensive end-to-end solutions across various broadcast segments. This award highlights Telerad's leadership in innovative broadcast solutions and its strong presence in western India.
13Aug 25
Ambalal Sarabhai Enterprises Reports Stellar Q1 Performance with 2270% Profit Surge
Ambalal Sarabhai Enterprises (ASE) reported a consolidated net profit of Rs. 822.35 lakhs for Q1, a 2270% increase from Rs. 34.71 lakhs in the same quarter last year. Revenue from operations slightly decreased by 0.88% to Rs. 4,033.88 lakhs. The company's pharmaceuticals segment generated Rs. 2,546.42 lakhs, while electronics contributed Rs. 1,487.46 lakhs. On a standalone basis, profit after tax grew by 1391% to Rs. 690.85 lakhs. ASE's Board of Directors formed a new Pharma Committee to oversee pharmaceutical operations, compliance, and business performance.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Lupin
Mankind Pharma
Laurus Labs
Dr Reddys Laboratories
Aurobindo Pharma
1,990.50
(-0.53%)
8,056.00
(+2.82%)
5,122.80
(+5.15%)
1,473.20
(+0.46%)
1,126.80
(+1.05%)
2,415.00
(-0.26%)
2,469.60
(-4.13%)
1,816.20
(+1.96%)
1,148.10
(+0.29%)
1,580.20
(+0.25%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
